ANCA-associated vasculitis
| Disease | Author, reference no | No |
| WG | Keogh et al368 | 10: Effective |
| WG/MPA | Stasi et al369 | 10: 8 WG/2 MPA: Effective |
| WG/MPA | Eriksson et al370 | 9: 7 WG/2 MPA: Effective |
| WG/MPA | Keogh et al371 | 11: 10 WG/1 MPA: Effective |
| WG/MPA/CSS | Smith et al372 | 11: 5 WG/5 MPA/1 CSS: Effective |
| WG | Aries et al373 | 8: Granulomatous manifestations: Effective in 3; no response in 3; ineffective 2 |
| WG | Brihaye et al374 | 8: Refractory/relapsing: Effective |
| WG | Henes et al375 | 6: Refractory: Effective |
| WG | Golbin et al376 | 28: Refractory: Effective |
| WG | Sailler et al377 | 37: 3 WG; 19 autoimmune cytopenia; 5 autoimmune coagulation disorder; 7 cryoglobulinaemia; 2 pemphigus; 1 SLE Effective: increased incidence of SAE |
| ANCA vasculitis | Lovric et al378 | 15: Refractory ANCA associated vasculitis: Effective |
| WG | Seo et al379 | 8: Effective |
| ANCA associated | Roccatello et al380 381 | 7: Effective |
| WG | Martinez Del Pero et al382 | 34: Effective |
| WG | Guillevin et al383 | 21: As effective as infliximab |
| WG | Ramos-Casals et al384 | 8: Effective |
| WG | Palm et al385 | 9: Effective: suppressing inflammation not airway stenosis |
| Refractory WG | Cohen et al386 | 22: As effective as infliximab |
ANCA, antineutrophil cytoplasmic antibodies; CSS, Churg–Strauss syndrome; MPA, microscopic polyangiitis; SAE, serious adverse event; SLE, systemic lupus erythematosus; WG, Wegener’s granulomatosis.